Kelun-Biotech
China-based corporation with a broad pipeline targeting unmet needs in oncology and other serious diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 3.6x EV/Revenue -17.8x EV/EBITDA | round | |
| N/A | €0.0 | round | |
* | N/A | $250m | Post IPO Equity |
| Total Funding | 000k | ||
| CNY | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 2387 % | 92 % | 25 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (2335 %) | (44 %) | (21 %) | (4 %) |
| Profit | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (2753 %) | (77 %) | (37 %) | (14 %) |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 2251 % | 105 % | 67 % | 62 % |
Source: Company filings or news article
Related Content
Kelun-Biotech is a pioneering biopharmaceutical company specializing in the development of innovative therapies for cancer and autoimmune diseases. Operating in the highly competitive biotechnology sector, Kelun-Biotech leverages its proprietary Antibody-Drug Conjugate (ADC) technology to create targeted treatments that improve patient outcomes. The company's primary clients include healthcare providers, research institutions, and pharmaceutical companies seeking cutting-edge solutions for complex medical conditions. Kelun-Biotech's business model revolves around research and development, clinical trials, and strategic partnerships with industry leaders to bring its products to market. Revenue is generated through licensing agreements, milestone payments, and eventual product sales.
Keywords: biopharmaceuticals, cancer, autoimmune diseases, ADC technology, targeted therapies, research and development, clinical trials, strategic partnerships, licensing agreements, milestone payments.
Investments by Kelun-Biotech
Edit